David P. Meeker - Feb 1, 2024 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role: President and CEO, Director
Signature: /s/ Hunter Smith, Attorney-in-Fact for David Meeker
Stock symbol: RYTM
Transactions as of: Feb 1, 2024
Transactions value $: -$196,507
Form type: 4
Date filed: 2/5/2024, 06:53 PM
Previous filing: Jun 30, 2023
Next filing: Feb 21, 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RYTM	Common Stock	Options Exercise		+14.1K	+12.69%		125K	Feb 1, 2024	Direct	F1
transaction	RYTM	Common Stock	Sale	-$197K	-4.36K	-3.48%	$45.06	121K	Feb 1, 2024	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RYTM	Restricted Stock Units	Options Exercise	$0	-14.1K	-25%	$0.00	42.4K	Feb 1, 2024	Common Stock	14.1K		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2	The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
F3	The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date.